Electronic Supplementary Material (ESI) for Food & Function.

Supplementary Information

Fig. S1 Schematic diagram of animal treatment

Table S1 Primer sequences for qPCR amplification

Gene	Forward	Reverse
Reg-3γ	TTCCTGTCCTCCATGATCAAAA	CATCCACCTCTGTTGGGTTCA
Lysozyme	GAGACCGAAGCACCGACTATG	CGGTTTTGACATTGTGTTCGC
Cryptdin-4	GACCCAGAAGGATCTGCTCT	GCATATCAGATCTCTCGACGATTTTTC

Table S2 Primer sequences for fecal microbiota analysis

Gene	Forward	Reverse
16s	ACTCCTACGGGAGGCAGCAG	ATTACCGCGGCTGCTGG
Prevotella spp.	GGTGTCGGCTTAAGTGCCAT	CGGA(C/T)GTAAGGGCCGTGC
Bifidobacteria	GGGATGCTGGTGTGGAAGAGA	TGCTCGCGTCCACTATCCAGT
Roseburia spp.	GCGGTRCGGCAAGTCTGA	CCTCCGACACTCTAGTMCGAC
Lactobacillus	CACCGCTACACATGGAG	AGCAGTAGGGAATTCTTCCA
Clostridium coccoides	CGGTGACTAATACCGCATACGG	CCTTGCCGCCTACTCTCC
Enterococcus spp.	CCCTTATTGTTAGTTGCCATCATT	ACTCGTTGTACTTCCCATTGT
Enterobacteriaceae spp.	GTGCCAGCMGCCGCGGTAA	GCCTCAAGGGCACAACCTCCAAG

Table S3 Immune organ indexes. Data were mean ± SEM (n = 10). Significance was accepted at # p < 0.05, ## p < 0.01, ### p < 0.001 vs. the normal group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the model group.

Group (mg/10 g b.w.)	**N**	**M**	**C**	**AL**	**AM**	**AH**
Spleen index	21.59 ± 3.04	13.46 ± 2.17$^{###}$	12.29 ± 2.28	14.06 ± 3.39	13.01 ± .27	14.34 ± 2.95
Thymus index	16.23 ± 3.27	4.68 ± 1.96$^{###}$	5.78 ± 2.39	5.17 ± 1.72	5.08 ± 1.97	5.69 ± 2.06